46 results on '"Cerny, T."'
Search Results
2. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
3. PV-0123: Gender and secondary malignancies in rectal cancer patients with and without radiation therapy
4. Aggravation of Er Stress By Combination of Proteasome Inhibitors and Hiv Protease Inhibitors Results in Preferencial Killing of Triple-Negative Breast Cancer Cells in Vitro
5. 80P MANAGEMENT OF ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: A SINGLE CENTRE EXPERIENCE
6. 1430 POSTER Quantitative Analysis of PTEN-dependent Glycoprotein Patterns Reveals Predictive Biomarker Signature for Response of Human Patients to Docetaxel Therapy in Metastatic Castration Resistant Prostate Cancer (mCRPC)
7. 1311 Quantitative analysis of Pten conditional knockout mouse proteome reveals significant prognostic biomarkers for survival in metastatic castration resistant prostate cancer (CRPC)
8. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung
9. 63PD LUNG CANCER IN WOMEN IN ST. GALLEN, EASTERN SWITZERLAND. AN ANALYSIS OF SEX-ASSOCIATED DIFFERENCES IN SMOKING HABITS, DISEASE PRESENTATION AND SURVIVAL
10. Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer
11. Remission of diabetes while on sunitinib treatment for renal cell carcinoma
12. Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors
13. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)
14. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
15. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
16. O-032 Neoadjuvant therapy with docetaxel and cisplatin in patients with non-small cell lung cancer (NSCLC), stage IIIA, pN2: A large phase II study with 59 months of follow-up
17. P-286 Safety, tolerability and efficacy of a therapeutic vaccine for nicotine dependence
18. Advances in the treatment of non-Hodgkin's lymphoma
19. Treatment of hairy cell leukemia with cladribine(2-chlorodeoxyadenosine) by subcutaneous bolus injection:a phase II study
20. Neoadjuvant therapy with Docetaxel (TAX) and Cisplatin (CIS) in patients (pts) with non-small cell lung cancer (NSCLC), stage IIIA, N2 is highly active with few toxicities
21. Rituximab: Active treatment of central nervous system involvement by non-Hodgkin's lymphoma?
22. Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers
23. Immunodiagnosis of echinococcosis in cancer patients
24. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy
25. Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients
26. Ventricular arrhythmia and torsade de pointe: Dose limiting toxicities of the MDR-modulator S9788 in a phase I trial
27. Primary cervical malignant teratoma with a rib metastasis in an adult: Five-year survival after surgery and chemotherapy
28. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas
29. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia
30. Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer
31. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation
32. Book review
33. 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III–IV non-Hodgkin's lymphoma
34. F183. 5-Fluorouracil and blood viscosity
35. Early versus late alternating chemotherapy in small-cell lung cancer
36. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine
37. Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck
38. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue
39. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias
40. Cladribine and severe myelotoxicity
41. Phase I clinical study and pharmacological evaluation of oral etoposide phosphate (BMY-40481)
42. The enigma of ifosfamide encephalopathy
43. Phase II studies of 4’-iodo-4’-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers
44. Bioavailability of subcutaneous Ifosfamide and feasibility of continuous outpatient application in cancer patients
45. Ifosfamide by continuous infusion to prevent encephalopathy
46. Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.